September 9, 2026 · Phase 2 readout
TYRA Phase 2 readout: a negative outcome, -17.7%
On September 9, 2026, TYRA-300 — Tyra Biosciences, Inc. (Locally Advanced Urothelial Carcinoma) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -17.7% in the window around the event. It had already run +9.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$26.73
1d before
$22.01
Event day
$23.54
1d after
$25.07
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.6% expected); the stock actually moved -17.7%. Model confidence at the time: 100%.
See the full scored track recordPre-catalyst setup
+9.1%
30-day run-up
6830%
30-day volatility
1.8×
volume spike